| • |
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in ... (redOrbit) |
| | EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy ... |
| | Published Date : Thu, 02 Jul 2009 15:08:37 GMT |
| |
| • |
Early Glance: Biotechnology companies (INO News) |
| | (AP:NEW YORK) Shares of some top biotechnology companies are down at 10 a.m.: Amgen fell $.74 or 1.4 percent, to $52.02. Biogen Idec fell $.64 or 1.4 percent, to $46.13. |
| | Published Date : Thu, 02 Jul 2009 14:53:59 GMT |
| |
| • |
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in ... (PR Newswire via Yahoo! Finance) |
| | Lixte Biotechnology Holdings announced today that investigators of the National Institute of Neurological Disorders and Stroke and the National Cancer Institute , National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. |
| | Published Date : Thu, 02 Jul 2009 13:00:00 GMT |
| |
| • |
Forest Biotechnology Obstructed By Anti-Biotech Groups (Medical News Today) |
| | The potential of forest biotechnology to help address significant social and environmental issues is being strangled at birth by the rigid opposition of some groups and regulations that effectively preclude even the testing of genetically modified trees, scientists argue in a new report. |
| | Published Date : Wed, 01 Jul 2009 16:11:27 GMT |
| |
| • |
Early Glance: Biotechnology companies (INO News) |
| | (AP:NEW YORK) Shares of some top biotechnology companies are up at 10 a.m.: Amgen rose $.15 or .3 percent, to $53.09. Biogen Idec rose $1.04 or 2.3 percent, to $46.19. |
| | Published Date : Wed, 01 Jul 2009 14:55:14 GMT |
| |
| • |
Final Glance: Biotechnology companies (INO News) |
| | Amgen fell $1.29 or 2.4 percent, to $51.47. Biogen Idec fell $1.77 or 3.8 percent, to $45.00. |
| | Published Date : Thu, 02 Jul 2009 22:38:40 GMT |
| |
| • |
Anti-biotech Groups Obstruct Forest Biotechnology (redOrbit) |
| | The potential of forest biotechnology to help address significant social and environmental issues is being strangled at birth by the rigid opposition of some groups and regulations that effectively preclude even the testing of genetically modified trees, scientists argue in a new report.Steps must be taken to create a regulatory environment that considers genetically modified trees on a ... |
| | Published Date : Tue, 30 Jun 2009 19:48:19 GMT |
| |
| • |
Early Glance: Biotechnology companies (INO News) |
| | (AP:NEW YORK) Shares of some top biotechnology companies are mixed at 10 a.m.: Amgen fell $.05 or .1 percent, to $53.06. Biogen Idec fell $.85 or 1.8 percent, to $46.47. |
| | Published Date : Tue, 30 Jun 2009 16:10:31 GMT |
| |
| • |
Annual Shareholders Meeting of InNexus Biotechnology Inc: Shareholders Approve All Resolutions (Business Wire via Yahoo! Finance) |
| | BRITISH COLUMBIA, Canada----InNexus Biotechnology Inc today announced that its shareholders have approved all resolutions at the Annual Shareholders Meeting. |
| | Published Date : Tue, 30 Jun 2009 22:16:00 GMT |
| |
| • |
SA vaccine potential transcends borders (Adelaide Now) |
| | ADELAIDE-based biotechnology company Vaxine is a finalist in three categories at this year's Telstra Business Awards. |
| | Published Date : Fri, 03 Jul 2009 00:15:00 GMT |
| |
